ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its price target increased by Bank of America from $26.00 to $29.00 in a research note released on Thursday, The Fly reports. A number of other analysts have also recently issued reports on the company. Credit Suisse Group increased their target price on ACADIA Pharmaceuticals from $93.00 to […]
StockNews.com assumed coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) in a research report report published on Thursday morning. The brokerage issued a buy rating on the biopharmaceutical company’s stock. Several other brokerages have also recently weighed in on ACAD. Morgan Stanley upped their price target on ACADIA Pharmaceuticals from $19.00 to $20.00 […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) CFO Mark C. Schneyer sold 15,310 shares of the stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $22.50, for a total transaction of $344,475.00. Following the transaction, the chief financial officer now owns 21,905 shares in the company, valued […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) – Equities researchers at Cantor Fitzgerald increased their FY2023 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Thursday, April 27th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will post earnings of ($0.40) per share for […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its target price increased by Credit Suisse Group from $93.00 to $95.00 in a report published on Friday morning, The Fly reports. Several other equities analysts have also recently issued reports on the company. Mizuho reaffirmed a neutral rating and set a $20.00 price objective on shares of […]